作者
Elaine Brohan,Neerja Chowdhary,Tarun Dua,Corrado Barbui,Graham Thornicroft,Dévora Kestel,Amza Ali,Sawitri Assanangkornchai,Henry Brodaty,Vladimir Carli,Rabih El Chammay,Odille Chang,Pamela Y. Collins,Pim Cuijpers,Christopher Dowrick,Julian Eaton,Cleusa P. Ferri,Sandra Fortes,Michael P. Hengartner,Asma Humayun,Nathalie Jetté,Petrus J. de Vries,María Elena Medina‐Mora,Pratima Murthy,Dinah Nadera,Charles R. Newton,Michael Njenga,Olayinka Omigbodun,Afarin Rahimi‐Movaghar,Atıf Rahman,Palmira Fortunato dos Santos,Shekhar Saxena,Lakshmi Vijayakumar,Huali Wang,Pichayanan Wattanavitukul,Enat Yewnetu,Ken Carswell,Sudipto Chatterjee,Fatima Batool,Alexandra Fleischmann,Brandon Gray,Charlotte Hanlon,Fahmy Hanna,Dzmitry Krupchanka,Aiysha Malik,Mark van Ommeren,Vladimir Poznyak,Katrin Seeher,Chiara Servili,Inka Weissbecker,Florence Baingana,Lorenzo Bello,Andrea Bruni,A. Bigot,Chencho Dorji,Martin Vandendyck,Ledia Lazëri,Maristela Monteiro,Manju Rani,Khalid Saeed,Renato Oliveira e Souza,Wole Ameyan,Valentina Baltag,Francesco Branca,Bernadette Cappello,Giorgio Cometto,Suraya Dalil,Albis Francesco Gabrielli,Benedikt Huttner,Ernesto Jaramillo,Taskeen Khan,Jonathan King,Rüdiger Krech,Nathalie Roebbel,Nhan Viet Tran,Yasuo Sumi
摘要
Summary
The WHO Mental Health Gap Action Programme (mhGAP) guideline update reflects 15 years of investment in reducing the treatment gap and scaling up care for people with mental, neurological, and substance use (MNS) conditions. It was produced by a guideline development group and steering group, with support from topic experts, using quantitative and qualitative evidence and a systematic review of use of mhGAP. 90 recommendations from the 2015 guideline update were validated and endorsed for use in their current format. These are joined by 30 revised recommendations and 18 new recommendations, including a new module on anxiety. Psychological interventions are emphasised as treatments and digitally delivered interventions feature across many modules, as well as updated recommendations for psychotropic medicines. Research gaps identified include the need for evidence from low-resource settings and on the views of people with lived experience of MNS conditions. The revised recommendations ensure that mhGAP continues to offer high-quality, timely, transparent, and evidence-based guidance to support non-specialist health workers in low-income and middle-income countries in providing care to individuals with MNS conditions.